Literature DB >> 34181881

Heterologous vaccine regimens against COVID-19.

Talita Duarte-Salles1, Daniel Prieto-Alhambra2.   

Abstract

Entities:  

Year:  2021        PMID： 34181881     DOI： 10.1016/S0140-6736(21)01442-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

1.  Urban monitoring, evaluation and application of COVID-19 listed vaccine effectiveness: a health code blockchain study.

Authors:  Tao Wang; Chaoqun Li; Hongyan Li; Zheheng Li
Journal:  BMJ Open       Date:  2022-07-13       Impact factor: 3.006

2.  Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.

Authors:  Niklas Worm Andersson; Emilia Myrup Thiesson; Mona Vestergaard Laursen; Stine Hasling Mogensen; Jesper Kjær; Anders Hviid
Journal:  BMJ       Date:  2022-07-13

Review 3.  Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities.

Authors:  Shelan Liu; Min Kang; Na Zhao; Yali Zhuang; Shijian Li; Tie Song
Journal:  Med Rev (Berl)       Date:  2022-05-25

4.  Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force.

Authors:  Anna Carolina Faria Moreira Gomes Tavares; Ana Karla Guedes de Melo; Vítor Alves Cruz; Viviane Angelina de Souza; Joana Starling de Carvalho; Ketty Lysie Libardi Lira Machado; Lilian David de Azevedo Valadares; Edgard Torres Dos Reis Neto; Rodrigo Poubel Vieira de Rezende; Maria Fernanda Brandão de Resende Guimarães; Gilda Aparecida Ferreira; Alessandra de Sousa Braz; Rejane Maria Rodrigues de Abreu Vieira; Marcelo de Medeiros Pinheiro; Sandra Lúcia Euzébio Ribeiro; Blanca Elena Gomes Rios Bica; Kátia Lino Baptista; Izaias Pereira da Costa; Claudia Diniz Lopes Marques; Maria Lúcia Lemos Lopes; José Eduardo Martinez; Rina Dalva Neubarth Giorgi; Lícia Maria Henrique da Mota; Marcos Antônio Araújo da Rocha Loures; Eduardo Dos Santos Paiva; Odirlei André Monticielo; Ricardo Machado Xavier; Adriana Maria Kakehasi; Gecilmara Cristina Salviato Pileggi
Journal:  Adv Rheumatol       Date:  2022-01-17

5.  Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.

Authors:  Peter Nordström; Marcel Ballin; Anna Nordström
Journal:  Lancet Reg Health Eur       Date:  2021-10-18

6.  Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50.

Authors:  Junqing Xie; Shuo Feng; Xintong Li; Ester Gea-Mallorquí; Albert Prats-Uribe; Dani Prieto-Alhambra
Journal:  Nat Commun       Date:  2022-03-21       Impact factor: 14.919

7.  The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine.

Authors:  Marina Labella; Jose Antonio Céspedes; Inmaculada Doña; Mohamed H Shamji; Ioana Agache; Cristobalina Mayorga; Maria José Torres
Journal:  Allergy       Date:  2021-10-31       Impact factor: 14.710

Review 8.  Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.

Authors:  Thuy Trang Nguyen; Trang Ho Thu Quach; Thanh Mai Tran; Huynh Ngoc Phuoc; Ha Thi Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Biomed Pharmacother       Date:  2022-01-19       Impact factor: 6.529

9.  Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2.

Authors:  Eduardo Hermosilla; Ermengol Coma; Junqing Xie; Shuo Feng; Carmen Cabezas; Leonardo Méndez-Boo; Francesc Fina; Elisabet Ballo; Montserrat Martínez; Manuel Medina-Peralta; Josep Maria Argimon; Daniel Prieto-Alhambra
Journal:  Nat Commun       Date:  2022-03-23       Impact factor: 14.919

10.  Effect of Heterologous Vaccination Regimen with Ad5-nCoV CanSinoBio and BNT162b2 Pfizer in SARS-CoV-2 IgG Antibodies Titers.

Authors:  Maria Elena Romero-Ibarguengoitia; Diego Rivera-Salinas; Yodira Guadalupe Hernández-Ruíz; Ana Gabriela Armendariz-Vázquez; Arnulfo González-Cantú; Irene Antonieta Barco-Flores; Rosalinda González-Facio; Laura Patricia Montelongo-Cruz; Gerardo Francisco Del Rio-Parra; Miguel Ángel Sanz-Sánchez
Journal:  Vaccines (Basel)       Date:  2022-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.